Forging A Path to HCV Elimination: Simpler Tests and Affordable Generics
Publication • 2017In July 2017, 37 treatment activists from 17 countries—including 14 low- and middle-income countries (LMICs)—met with representatives from three generics and three diagnostics companies. This Hepatitis C World Community Advisory Board meeting was an opportunity for activists to present demands and obtain strategic information from companies on critical access issues in LMICs relating to pricing…
The Tuberculosis Treatment Pipeline: A Breakthrough Year for the Treatment of XDR-TB
Pipeline • 2017July 2017 By Marcus Low Editor’s note: This version has been modified from the original print version on August 7, 2017 to reflect recent updates and clarify the status of access to delamanid. INTRODUCTION Arguably, the most critical questions in TB treatment today are “What is the optimal regimen for the treatment of multi-drug resistant…
The Antiretroviral Pipeline
Pipeline • 2017July 2017 By Tim Horn INTRODUCTION The antiretroviral (ARV) pipeline remains robust, with several drugs, coformulations, and biologics currently in Phase II and III stages of development. The trends are clear: maximizing the safety and efficacy of standard three-drug regimens; validating two-drug regimens as durable maintenance therapy and, potentially, for people living with HIV starting…
2017 Symposium: Reframing Risk and Accountability for Action to ZERO TB
Webinars • 2017On October 12, 2017, in Guadalajara, Mexico, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health. Introduction – Erica Lessem (Treatment Action Group) and Eloisa “Louie” Zepeda-Teng (TB meningitis survivor, the Philippines) …
Changing WHO Global TB Program Leadership
Statement / Press • 2017TAG's Executive Director, Mark Harrington, congratulates Dr. Mario Raviglione on his retirement and thanks him for his efforts and the years of collaboration while he was director of the World Health Organization’s (WHO's) Global TB Program.
US Health & Human Services (HHS) Strategic Plan FY 2018-2022: TAG Comments to the Assistant Secretary for Planning and Evaluation
Letters • 2017TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.
Submission to the Office of the United Nations High Commissioner for Human Rights to Report on Sustainable Development Goals and Health
Letters • 2017A review of comments submitted by TAG to the Office of the United Nations High Commissioner for Human Rights, in response to a request for submissions from interested organizations and stakeholders for the preparation of its report on Sustainable Development Goals and Health.
HCV Pipeline: DAAs and Diagnostics in the Pangenotypic Era
Pipeline • 2017July 2017 By Annette Gaudino INTRODUCTION The continued development of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) has brought both multigenotypic and pangenotypic regimens to market, with more on the horizon. These simpler-to- prescribe regimens potentially eliminate the need for genotype testing, have shown improved efficacy in previously difficult-to-treat patients, and hold the promise…
The Tuberculosis Diagnostics Pipeline
Pipeline • 2017July 2017 By Erica Lessem INTRODUCTION Diagnosing tuberculosis (TB) is the first step to being able to treat it and prevent transmission. New guidelines from the World Health Organization (WHO) note that diagnosis should be “available free of charge to all persons with TB and populations at risk.”1 Yet an estimated over four million people…
Preventive Technologies: Antiretroviral and Vaccine Development
Pipeline • 2017July 2017 By Jeremiah Johnson and Richard Jefferys INTRODUCTION Recent advances in the research, development, and implementation of biomedical HIV prevention—primarily in the form of treatment as prevention (TasP) and tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC) as pre-exposure prophylaxis (PrEP)—already appear to be bearing fruit in addressing complex HIV epidemics. At this year’s Conference on…